Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients

Cancer Science

Volumn 102, Issue 6, 2011, Pages 1181-1187

  Kameshima, Hidekazu ^a   Tsuruma, Tetsuhiro ^a   Torigoe, Toshihiko ^b   Takahashi, Akari ^b   Hirohashi, Yoshihiko ^b   Tamura, Yasuaki ^b   Tsukahara, Tomohide ^b   Ichimiya, Shingo ^b   Kanaseki, Takayuki ^b   Iwayama, Yuji ^a   Sato, Noriyuki ^b   Hirata, Koichi ^a  

^a Departments of Surgery   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; HLA A24 ANTIGEN; SURVIVIN 2B80 88 VACCINE; SURVIVIN 2B80 88 VACCINE PLUS FREUND ADJUVANT; SURVIVIN 2B80 88 VACCINE PLUS FREUND ADJUVANT PLUS INTERFERON ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PREVENTION; CELL CLONING; CELL SELECTION; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; INJECTION SITE INDURATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ADULT; AGED; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HLA-A ANTIGENS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON TYPE I; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 79956225573     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01918.x     Document Type: Article

References (29)

1. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
2. Hirohashi Y, Torigoe T, Inoda S et al. The functioning antigens; beyond just as the immunological targets. Cancer Sci 2009; 100: 798-806.
3. Sato N, Hirohashi Y, Tsukahara T et al. Molecular pathologic approaches to human tumor immunology. Pathol Int 2009; 59: 205-17.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med 2004; 10: 909-15.
5. Tsukahara T, Torigoe T, Tamura Y, Kawaguchi S, Wada T, Sato N. Antigenic peptide vaccination: provoking immune response and clinical benefit for cancer. Curr Immunol Rev 2008; 4: 235-41.
6. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
7. Andersen MH, Becker JC, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4: 399-409.
8. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2004; 2: 19-29.
9. Tsuruma T, Iwayama Y, Ohmura T et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 2008; 6: 24-35.
10. Kawaguchi S, Wada T, Ida K et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med 2005; 3: 1-9.
11. Honma I, Kitamura H, Torigoe H et al. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009; 58: 1801-7.
12. Coulie PG, Karanikas V, Lurquin C. Cytolytic T-cell response of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002; 188: 33-42.
13. Nagaraj S, Pisarev V, Kinarsky L et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 2007; 30: 169-79.
14. Hirohashi Y, Torigoe T, Inoda S et al. Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells. Immunotherapy 2010; 2: 201-11.
15. Nakatsugawa M, Hirohashi Y, Torigoe T et al. Novel spliced form of a lens protein as a novel lung cancer antigen, Lengsin splicing variant 4. Cancer Sci 2009; 100: 1485-93.
16. Honma I, Torigoe T, Hirohashi Y et al. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. J Transl Med 2009; 7: 103-10.
17. Inoda S, Hirohashi Y, Torigoe T et al. Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma. J Immunother 2009; 32: 474-85.
18. Sato E, Torigoe T, Hirohashi Y et al. Identification of immunogenic CTL epitopes of HIFPH3 for specific immunotherapy of renal cell carcinoma. Clin Cancer Res 2008; 14: 6916-23.
19. Hirohashi Y, Torigoe T, Maeda A et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002; 8: 1731-9.
20. Idenoue S, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-82.
21. Hariu H, Hirohashi Y, Torigoe T et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005; 11: 1000-9.
22. Le Bon A, Etchart N, Rossmann C et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-15.
23. Dikopoulos N, Bertoletti A, Kroeger A, Hauser H, Schirmbeck R, Reimann J. Type I IFN negatively regulates CD8+ T cell responses through IL-10-producing CD4+ T regulatory 1 cells. J Immunol 2005; 174: 99-109.
24. Di Pucchio T, Pilla L, Capone I et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 4943-51.
25. Gigante M, Mandic M, Wesa AK et al. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients. J Immunother 2008; 31: 254-62.
26. Badovinac VP, Messingham KN, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nature Med 2005; 11: 748-56.
27. Kurotaki T, Tamura Y, Ueda G et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol 2007; 179: 1803-13.
28. Kutomi G, Tamura Y, Okuya K et al. Targeting to static endosome is required for efficient cross-presentation of endoplasmic reticulum-resident oxygen regulated protein 150 (ORP150)-peptide complexes. J Immunol 2009; 183: 5861-9.
29. Okuya K, Tamura Y, Saito K et al. Extracellular heat shock protein 90 (Hsp90) directs self-DNA to static early endosome-resident TLR-9, leading to type I interferon production. J Immunol 2010; 184: 7092-9.